Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 17/20 | 0.47 |
| ▸ | CCNK | O75909 | 17/20 | 0.47 |
| ▸ | CDK9 | P50750 | 17/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 17/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.47 |
| ▸ | CDK2 | P24941 | 14/20 | 0.47 |
| ▸ | CDK7 | P50613 | 11/20 | 0.42 |
| ▸ | CCNH | P51946 | 10/20 | 0.42 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268925 | 0.83 | CCNK (0.50) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL269583 | 0.83 | CCNK (0.50) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL30259588 | 0.74 | KDM4E (0.61) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25258456 | 0.73 | IDH2 (0.56) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25222649 | 0.73 | IDH2 (0.56) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL28312479 | 0.73 | IDH2 (0.56) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL17961848 | 0.73 | CCNT1 (0.41) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL17961847 | 0.73 | CCNT1 (0.41) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL30833890 | 0.72 | IDH2 (0.41) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25294691 | 0.71 | CCNT1 (0.41) | CCNT1CCNKCDK9CDK12CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347571-B1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | HOFFMANN LA ROCHE (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12421209-B2 | Compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250276958-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250197370-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20240132471-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4347571-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-117460718-A | Triazine derivatives and their use in the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2022253936-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253936-A1 | TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421209-B2 | Compounds | C5, RB1, RPS4X | CCNT1 115/4885CCNK 311/4885CDK9 658/4885 |
| US-20250276958-A1 | COMPOUNDS | C5, RB1, RPS4X | CCNT1 115/4885CCNK 311/4885CDK9 658/4885 |
| US-20250197370-A1 | NOVEL COMPOUNDS | RB1, CDK11B, RPS4X | CCNT1 311/4885CCNK 484/4885CDK9 871/4885 |
| US-20240132471-A1 | NOVEL COMPOUNDS | RB1, RPS4Y1, CDK11B | CCNT1 294/4885CCNK 572/4885CDK9 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.